Health Care & Life Sciences » Biotechnology | Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc.
Stock Exchange Frankfurt Stock Exchange
EPS
EUR18.27
Market Cap
EUR30.81 B
Shares Outstanding
106.14 M
Public Float
77.68 M
Regeneron Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$21.13
Market Cap
$33.66 B
Shares Outstanding
107.73 M
Public Float
81.09 M
Regeneron Pharmaceuticals Inc.
Stock Exchange SIX Swiss Exchange
EPS
-
Market Cap
-
Shares Outstanding
106.14 M
Public Float
77.68 M

Profile

Address
777 Old Saw Mill River Road
Tarrytown New York 10591
United States
Employees -
Website http://www.regeneron.com
Updated 07/08/2019
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G.

Financials

View All

P. Roy Vagelos
Chairman
George Damis Yancopoulos
Co-President, Director & Chief Scientific Officer